LSM12 Antibody

What is LSM12 and why is it important in cancer research?

LSM12 is an RNA-splicing factor belonging to the Sm family involved in RNA processing. It has gained significance in cancer research due to its upregulation in various malignancies. In OSCC, LSM12 is significantly upregulated compared to paired normal tissues, with a 100% positive rate in OSCC tissues versus 91.1% negative rate in normal tissues . Studies show LSM12 promotes cell growth, colony formation, migration, and invasion in cancer cells, while its knockdown inhibits these malignant phenotypes and tumor formation in vivo . LSM12 also regulates alternative splicing of tumor-related genes, making it a potential biomarker and therapeutic target.

What types of LSM12 antibodies are available for research?

Based on research protocols, LSM12 antibodies commonly used in laboratories include rabbit anti-LSM12 monoclonal antibodies, such as those from Abcam (typically used at 1:10000 dilution for Western blotting) . Both polyclonal and monoclonal antibodies are available, with monoclonal antibodies offering greater specificity for particular epitopes of the LSM12 protein. Researchers should select antibodies validated for their specific applications, whether for Western blotting, immunohistochemistry, immunofluorescence, or immunoprecipitation.

What is the molecular weight of LSM12 and how does this affect antibody selection?

LSM12 has a molecular weight that should be considered when selecting antibodies and designing experiments. When performing Western blotting, researchers should expect to visualize LSM12 at its predicted molecular weight. Any deviation might indicate post-translational modifications, alternative splicing variants, or proteolytic degradation. Always verify antibody specifications to ensure they recognize the appropriate isoforms of LSM12 relevant to your research.

How can LSM12 antibodies be used to study cancer progression?

LSM12 antibodies are valuable tools for investigating cancer progression through multiple approaches:

• Tissue analysis: Immunohistochemistry using LSM12 antibodies can assess expression patterns across tumor tissues compared to normal tissues. Studies have shown that in OSCC tissues, LSM12 expression has a 100% positive rate with strong staining throughout the tissues in 92.1% of cases, while normal tissues show 91.1% negative rate .

• Cellular studies: Western blotting with LSM12 antibodies can quantify protein levels in various cancer cell lines. This approach has confirmed significantly higher LSM12 expression in LSM12-overexpressing SCC-25 and CAL 27 cells compared to control cells .

• Functional analysis: Using LSM12 antibodies in conjunction with knockdown or overexpression studies helps correlate LSM12 levels with cancer cell behaviors like proliferation, migration, and invasion.

What role does LSM12 play in different cancer types and how can antibodies help characterize this?

LSM12 has been implicated in multiple cancer types. In OSCC, LSM12 is significantly upregulated in clinical samples . Analysis using the GEPIA database indicates LSM12 is also upregulated in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), and colon adenocarcinoma (COAD) . In colorectal cancer, LSM12 facilitates cancer progression by activating specific signaling pathways .

LSM12 antibodies enable researchers to:

• Compare expression across different cancer types

• Correlate expression with clinical features and patient outcomes

• Investigate subcellular localization in different cancer contexts

• Examine protein-protein interactions specific to each cancer type

How can LSM12 antibodies be used to validate knockdown or overexpression models?

LSM12 antibodies are essential for confirming the efficacy of genetic manipulations in experimental models. For knockdown validation:

• Western blotting: Primary LSM12 antibodies (such as rabbit anti-LSM12 monoclonal antibody at 1:10000 dilution) can be used with HRP-conjugated secondary antibodies to quantify protein reduction .

• Immunofluorescence: LSM12 antibodies help visualize protein reduction in individual cells and assess transfection efficiency in experiments using lentiviral shRNA systems .

For LSM12 overexpression models, these same techniques confirm increased protein levels, with antibodies against tagged versions (e.g., anti-Flag antibodies at 1:500 dilution) providing an alternative detection method .

What are the optimal conditions for using LSM12 antibodies in Western blotting?

For optimal Western blotting with LSM12 antibodies:

• Sample preparation: Harvest cells and lyse them in an appropriate buffer. Quantify protein extracts using QuantiPro BCA Assay Kit or similar .

• Protein separation: Separate equal quantities of protein by SDS-PAGE and transfer to PVDF membranes.

• Blocking: Block membranes with 5% skim milk to reduce non-specific binding.

• Primary antibody incubation: Incubate overnight with rabbit anti-LSM12 monoclonal antibody (1:10000 dilution for Abcam antibodies) .

• Secondary antibody: Incubate with HRP-conjugated anti-rabbit IgG for 2 hours at room temperature.

• Loading control: Use β-actin or GAPDH as internal controls.

• Detection: Visualize bands using an imaging system such as ImageQuant LAS 4000 .

What are the best practices for using LSM12 antibodies in immunohistochemistry?

For immunohistochemistry with LSM12 antibodies:

• Tissue preparation: Use formalin-fixed, paraffin-embedded tissue sections or tissue microarrays.

• Antigen retrieval: Perform appropriate antigen retrieval methods (heat-induced or enzymatic) to expose epitopes.

• Antibody dilution: Determine optimal antibody dilution through titration experiments.

• Scoring system: Implement a consistent scoring system for LSM12 expression. Studies have used systems that evaluate staining intensity and percentage of positive cells .

• Controls: Include positive controls (known LSM12-expressing tissues) and negative controls (antibody diluent only) to validate staining specificity.

When analyzing results, note that in OSCC studies, LSM12 staining patterns differ significantly between cancer and normal tissues. In normal tissues, weak positive staining is confined to basal or lower spinous layers, while in OSCC tissues, strong staining spreads throughout the tissue .

How should LSM12 antibodies be validated before experimental use?

Proper validation of LSM12 antibodies is crucial for experimental reliability:

• Western blot validation: Confirm antibody specificity by detecting a single band at the expected molecular weight in positive control samples, with reduced signal in knockdown samples.

• Positive and negative controls: Include known LSM12-expressing cell lines (like SCC-25 or CAL 27) as positive controls and LSM12 knockdown cells as negative controls .

• Blocking peptide: Perform a blocking peptide competition assay where pre-incubation of the antibody with an excess of the immunizing peptide should eliminate specific signals.

• Cross-reactivity assessment: Test the antibody against related proteins to ensure specificity for LSM12.

• Application-specific validation: Validate the antibody separately for each application (Western blot, IHC, IF, IP) as performance can vary by application.

What are common issues when using LSM12 antibodies in Western blotting and how can they be resolved?

When working with LSM12 antibodies in Western blotting, researchers may encounter:

• Weak or no signal:

  • Increase antibody concentration or incubation time

  • Verify protein transfer efficiency

  • Enhance signal using more sensitive detection reagents

  • Check sample preparation for potential protein degradation

• Multiple bands or non-specific binding:

  • Increase blocking time or concentration

  • Use more stringent washing conditions

  • Optimize primary antibody dilution (1:10000 dilution has been successful for some anti-LSM12 antibodies)

  • Consider alternative antibody clones with higher specificity

• Inconsistent results between replicates:

  • Standardize sample preparation and protein quantification

  • Maintain consistent transfer conditions

  • Use internal loading controls (β-actin or GAPDH)

  • Prepare fresh reagents for each experiment

How can LSM12 antibody signals be optimized for immunofluorescence in cancer cell lines?

To optimize immunofluorescence with LSM12 antibodies:

• Fixation method: Test different fixation methods (paraformaldehyde, methanol, or acetone) to determine which best preserves LSM12 epitopes while maintaining cellular morphology.

• Permeabilization: Adjust permeabilization conditions (Triton X-100 concentration and time) to enable antibody access to intracellular LSM12 without disrupting cellular structures.

• Blocking: Use appropriate blocking solutions (e.g., 5% normal serum from the same species as the secondary antibody) to reduce background.

• Antibody titration: Perform a dilution series to determine optimal concentration that maximizes specific signal while minimizing background.

• Mounting media: Use mounting media with anti-fade properties to preserve fluorescence during microscopy.

• Controls: Include cells with LSM12 knockdown as negative controls and LSM12-overexpressing cells as positive controls .

What strategies can improve LSM12 detection in tissues with low expression?

For detecting low levels of LSM12 in tissues:

• Signal amplification systems: Use tyramide signal amplification (TSA) or polymer-based detection systems to enhance sensitivity.

• Extended antibody incubation: Increase primary antibody concentration or extend incubation time (overnight at 4°C).

• Alternative antibody clones: Test multiple antibody clones to identify those with higher affinity for LSM12.

• Improved antigen retrieval: Optimize antigen retrieval methods to better expose LSM12 epitopes in fixed tissues.

• Fresh frozen tissues: For some applications, fresh frozen tissues may preserve antigenicity better than FFPE samples.

• Confocal microscopy: Use confocal microscopy with appropriate filters to detect weak signals with reduced background.

How can LSM12 antibodies be used to study its role in RNA splicing and gene regulation?

LSM12, as an RNA-splicing factor, significantly impacts gene regulation. Researchers can use LSM12 antibodies to investigate these functions through:

• RNA immunoprecipitation (RIP): LSM12 antibodies can pull down LSM12-RNA complexes to identify directly bound RNA targets. This can reveal how LSM12 regulates specific transcripts like USO1, where LSM12 has been shown to affect exon 15 inclusion .

• Chromatin immunoprecipitation (ChIP): Although LSM12 primarily functions in RNA processing, ChIP with LSM12 antibodies can examine potential roles in transcriptional regulation or chromatin association.

• Co-immunoprecipitation (Co-IP): LSM12 antibodies can isolate protein complexes to identify interaction partners in the splicing machinery, providing insights into its mechanistic role.

• Immunofluorescence co-localization: Dual staining with LSM12 antibodies and markers of splicing speckles or other RNA processing bodies can reveal subcellular sites of LSM12 activity.

• Proximity ligation assay (PLA): This technique can detect and visualize LSM12 interactions with splicing factors in situ with high sensitivity.

What approaches can be used to study LSM12 phosphorylation or other post-translational modifications?

To investigate LSM12 post-translational modifications:

• Phospho-specific antibodies: If available, phospho-specific LSM12 antibodies can directly detect phosphorylated forms of the protein.

• Phos-tag gels: Using standard LSM12 antibodies with Phos-tag SDS-PAGE can separate phosphorylated from non-phosphorylated forms based on mobility shift.

• Immunoprecipitation followed by mass spectrometry: LSM12 antibodies can immunoprecipitate the protein, which can then be analyzed by mass spectrometry to identify specific modification sites.

• Treatment with phosphatases: Comparing LSM12 migration patterns before and after phosphatase treatment can reveal whether phosphorylation affects protein mobility.

• Kinase inhibitors: Using kinase inhibitors followed by LSM12 immunoblotting can help identify kinases responsible for LSM12 phosphorylation.

How can LSM12 antibodies be used to investigate protein-protein interactions in the context of alternative splicing regulation?

To study LSM12's protein-protein interactions in splicing regulation:

• Co-immunoprecipitation: Use LSM12 antibodies to pull down LSM12 and its interacting partners, followed by Western blotting or mass spectrometry to identify components of regulatory complexes .

• Reciprocal Co-IP: Confirm interactions by performing reverse Co-IP with antibodies against suspected binding partners.

• Proximity-dependent biotin identification (BioID): This approach can identify proteins in close proximity to LSM12 in living cells, providing insight into its interaction network.

• Immunofluorescence co-localization: Double staining with LSM12 antibodies and antibodies against other splicing factors can visualize potential interactions within splicing complexes.

• FRET (Fluorescence Resonance Energy Transfer): Using fluorescently-labeled antibodies or fusion proteins to detect close associations between LSM12 and other proteins.

These methods can help elucidate how LSM12 regulates alternative splicing of specific exons, such as USO1 exon 15, which has been shown to influence malignant phenotypes in OSCC cells .